Equities research analysts predict that Medidata Solutions Inc (NASDAQ:MDSO) will post $140.76 million in sales for the current quarter, according to Zacks. Six analysts have provided estimates for Medidata Solutions’ earnings, with the lowest sales estimate coming in at $140.20 million and the highest estimate coming in at $141.34 million. Medidata Solutions reported sales of $124.47 million in the same quarter last year, which indicates a positive year over year growth rate of 13.1%. The company is scheduled to issue its next quarterly earnings results on Thursday, February 8th.
On average, analysts expect that Medidata Solutions will report full-year sales of $140.76 million for the current year, with estimates ranging from $544.50 million to $546.00 million. For the next financial year, analysts forecast that the business will report sales of $641.57 million per share, with estimates ranging from $635.19 million to $650.00 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Thursday, October 26th. The company reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The company had revenue of $140.08 million during the quarter, compared to analysts’ expectations of $141.27 million. During the same quarter in the prior year, the company posted $0.28 earnings per share. Medidata Solutions’s revenue for the quarter was up 16.7% compared to the same quarter last year.
Shares of Medidata Solutions (NASDAQ:MDSO) opened at $66.86 on Monday. Medidata Solutions has a 52-week low of $47.77 and a 52-week high of $85.92. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.37 and a current ratio of 1.29. The company has a market cap of $3,908.70, a P/E ratio of 95.52, a P/E/G ratio of 3.46 and a beta of 1.69.
In other news, EVP Michael I. Otner sold 10,000 shares of the stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $70.88, for a total value of $708,800.00. Following the sale, the executive vice president now owns 80,674 shares in the company, valued at $5,718,173.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Tarek Sherif sold 200,000 shares of the stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $68.76, for a total transaction of $13,752,000.00. The disclosure for this sale can be found here. Insiders sold 239,010 shares of company stock worth $16,437,036 in the last quarter. Company insiders own 5.80% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Fortaleza Asset Management Inc. acquired a new stake in Medidata Solutions during the third quarter valued at $155,000. Polen Capital Management LLC acquired a new stake in Medidata Solutions during the third quarter valued at $205,000. Cubist Systematic Strategies LLC acquired a new stake in Medidata Solutions during the second quarter valued at $227,000. ETF Managers Group LLC acquired a new stake in Medidata Solutions during the second quarter valued at $233,000. Finally, Hanseatic Management Services Inc. grew its position in Medidata Solutions by 14,915.0% during the third quarter. Hanseatic Management Services Inc. now owns 3,003 shares of the company’s stock valued at $234,000 after buying an additional 2,983 shares during the period.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.